Literature DB >> 26084826

Hyperbaric Oxygen Treatments Attenuate the Neutrophil-to-Lymphocyte Ratio in Patients with Idiopathic Sudden Sensorineural Hearing Loss.

Hang Li1, Daqing Zhao2, Mingfang Diao3, Chen Yang1, Yu Zhang1, Yan Lv1, Jinjing Zhao1, Shuyi Pan4.   

Abstract

OBJECTIVE: Hyperbaric oxygen therapy (HBOT) is a promising treatment in the management of idiopathic sudden sensorineural hearing loss (ISSNHL), but the specific mechanisms of HBOT in ISSNHL are still unclear. The curative effects of HBOT in many diseases are related to the attenuation of inflammatory response. The neutrophil-to-lymphocyte ratio (NLR) is a new inflammatory marker that can be assessed quickly. We investigated the relationship between HBOT and the inflammatory response in ISSNHL using the NLR. STUDY
DESIGN: Case series with chart review
SETTING: Tertiary teaching and research hospital SUBJECTS AND METHODS: Between December 2007 and December 2013, 41 ISSNHL patients who underwent HBOT, 45 ISSNHL patients who did not undergo HBOT, and 14 healthy control subjects who underwent HBOT were included in the study. NLRs were assessed at 2 time points: at baseline (pretreatment) and on day 1 after 10 sessions of HBOT (posttreatment). Audiometric testing was performed at the above 2 time points.
RESULTS: The mean post-HBOT NLRs, neutrophil, and white blood cell count values of the ISSNHL patients were significantly lower than their pretreatment values (P < .001). Compared with the ISSNHL patients who did not undergo HBOT, the posttreatment NLR levels of the ISSNHL patients who underwent HBOT were much lower (P = .036). Higher relative hearing gains were significantly associated with a greater reduction in the NLR after HBOT (r = -0.885, P = .001).
CONCLUSIONS: The beneficial effect of HBOT on ISSNHL may be mediated at least in part by a decrease of inflammation. © American Academy of Otolaryngology-Head and Neck Surgery Foundation 2015.

Entities:  

Keywords:  hyperbaric oxygen therapy (HBOT); idiopathic sudden sensorineural hearing loss (ISSNHL); inflammation; inflammatory marker; neutrophil-to-lymphocyte ratio (NLR)

Mesh:

Year:  2015        PMID: 26084826     DOI: 10.1177/0194599815589072

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  6 in total

1.  Prognostic factors for hearing outcomes in patients that undergo adjuvant hyperbaric oxygen therapy for sudden sensorineural hearing loss.

Authors:  Zirong Huo; Xuefeng Cheng; Jian Gu; Yingying Hong; Zhentao Wang; Zhihua Zhang
Journal:  Laryngoscope Investig Otolaryngol       Date:  2022-03-10

Review 2.  Neutrophil-to-lymphocyte ratio predicts diagnosis and prognosis of idiopathic sudden sensorineural hearing loss: A systematic review and meta-analysis.

Authors:  Liquan Chen; Gaohua Zhang; Zhanhui Zhang; Yufeng Wang; Liren Hu; Jiayuan Wu
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

3.  Markers of Pulmonary Oxygen Toxicity in Hyperbaric Oxygen Therapy Using Exhaled Breath Analysis.

Authors:  T T Wingelaar; P Brinkman; P J A M van Ooij; R Hoencamp; A H Maitland-van der Zee; M W Hollmann; R A van Hulst
Journal:  Front Physiol       Date:  2019-04-24       Impact factor: 4.566

4.  Effect of intermittent hyperoxia on stem cell mobilization and cytokine expression.

Authors:  Kent J MacLaughlin; Gregory P Barton; Rudolf K Braun; Marlowe W Eldridge
Journal:  Med Gas Res       Date:  2019 Jul-Sep

5.  Is nucleate cell count and neutrophil to lymphocyte ratio related to patients with audiographically distinct sudden sensorineural hearing loss?

Authors:  Yuanyuan Sun; Liang Xia; Hui Wang; Zhengnong Chen; Yaqin Wu; Bin Chen; Haibo Shi; Yanmei Feng; Shankai Yin
Journal:  Medicine (Baltimore)       Date:  2018-05       Impact factor: 1.889

6.  Differences in platelet-related parameters among patients with audiographically distinct sudden sensorineural hearing loss: A retrospective study.

Authors:  Yuanyuan Sun; Yang Guo; Hui Wang; Zhengnong Chen; Yaqin Wu; Haibo Shi; Yanmei Feng; Shankai Yin
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.